<DOC>
	<DOCNO>NCT01585207</DOCNO>
	<brief_summary>The purpose study determine vigabatrin , unusual anti-seizure medication , diminish Tourette Disorder outbursts young adult whose symptom persist adulthood respond usual treatment .</brief_summary>
	<brief_title>Proof-of-Concept Safety Study CPP-109 ( Vigabatrin ) Treatment Refractory Tourette 's Disorder</brief_title>
	<detailed_description>The aim study 1 ) explore proof concept CPP-109 reduce tic , 2 ) obtain systematic data regard dosing , safety tolerability CPP-109 adult treatment refractory TD . We obtain preliminary data estimate effect size tic use Cohen 's , calculate difference two mean ( baseline endpoint score YGTSS ) , divide standard deviation difference .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Vigabatrin</mesh_term>
	<criteria>1 . Subjects must 18 35 year age ( inclusive ) inform consent obtain . 2 . Subjects must meet full DSMIV diagnostic criterion TD clinical interview examination physician investigator , confirm Structured Clinical Interview DSM ( SCIDCT ) clinical trial . 3 . Subjects fail respond adequate trial , determine investigator , clonidine , guanfacine , first generation ( typical ) secondgeneration ( atypical ) neuroleptic medication past . 4 . Tics cause significant distress impairment , determine subject principal investigator , current treatment regimen . 5 . Laboratory result , include serum chemistry , hematology , urinalysis , must show significant abnormality ( significant define laboratory value require acute medical intervention ) . 6 . Subjects undergo formal IQ testing , must normal intelligence judgment investigator . 7 . Subjects must possess educational level , degree understand command English language enable communicate suitably investigator study coordinator , understand nature study . 8 . Subjects must consider reliable . 9 . Written inform consent subject obtain . 1 . Subjects organic brain disease , example , traumatic brain injury residuum . 2 . Subjects preexist ophthalmologic condition . 3 . Subjects high risk type irreversible vision loss require drug associate serious adverse ophthalmic effect retinopathy glaucoma . 4 . Subjects meet criterion mental retardation define DSMIVTR . 5 . Subjects history seizure disorder ( febrile seizure ) . 6 . Subjects history Sydenham 's Chorea . 7 . Subjects autism , schizophrenia , psychotic disorder , bipolar disorder . 8 . Subjects primary diagnosis major mood disorder require ongoing psychiatric treatment . 9 . Subjects neurological disorder tic disorder . 10 . Subjects major medical illness . 11 . Female subject unwilling use birth control pregnant , determine serum pregnancy test baseline assessment , lactate . 12 . Subjects past current history substance dependence and/or current history substance abuse fail baseline toxicology screen . 13 . Subjects clinically significant abnormal laboratory result baseline screen include EKG , blood test . 14 . Subjects , opinion investigator , unsuitable way participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Tourette 's Disorder</keyword>
	<keyword>vigabatrin</keyword>
</DOC>